Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

9342-8530 Quebec Inc DGCRF

Diagnocure Inc is a Canada based biotechnology company. It is primarily engaged in the business activity of development and commercialization of products relating to the diagnosis of cancer. The group generates its revenue from research and license agreement. The head office of the company is located in Quebec, Canada.


GREY:DGCRF - Post by User

Bullboard Posts
Post by ready2go1on Jun 23, 2009 9:34pm
301 Views
Post# 16093341

$2.00 share price

$2.00 share priceLooking at  Epigenomics market cap vs Diagnocure's; we should be sitting at $2.00... TODAY.
Epigenomics is currently working towards where Diagnocure has already been. PCA3 and our GCC test have a leg up over anything that they currently have. The GCC blood test study is completed and we will see results published shortly.
     I am looking forward to hearing the results of the European screening study using PCA3 and the start of the U.S. FDA trial. There are still a number of studies taking place both here in the U.S. and in Europe that will continue to show the utility of the PCA3 test.
     Its a shame that the share price and the progress made by the company, moving forward with the FDA trial and GCC, are moving in opposite directions for the time being, secondary to a program sell that has held us down for the past 5 wks. I thought we were close to breaking out with the decent volume day and the good bid order that we had at the end of the day Monday but everyone is patient and in time we will get there and past our expectations.
Bullboard Posts